The DOI matches its Crossref record; 166 of the 166 references it cites were found in a registry or an index.
Cell cycle kinases as therapeutic targets for cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“In complex with cyclin A, CDK1 is abruptly activated at the transition from the second gap (G2) phase to the mitosis (M) phase to facilitate the commencement of mitosis through regulation of chromosome condensation and microtubule dynamic”
BackgroundATM and related protein kinases: safeguarding genome integrity
Shiloh, Y. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1011 · Cited by 2,577
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Borst, O., Walker, B., Münzer, P., Russo, A., Schmid, E., Faggio, C., Bigalke, B., Laufer, S., Gawaz, M., & Lang, F. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350110 · Cited by 1,860
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Chk1 and Chk2 kinases in checkpoint control and cancer
Bartek, J., & Lukas, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00110-7 · Cited by 1,513
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Hickson, I., Zhao, Y., Richardson, C. J., Green, S. J., Martin, N. M. B., Orr, A. I., Reaper, P. M., Jackson, S. P., Curtin, N. J., & Smith, G. C. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2727 · Cited by 1,220
Giacinti, C., & Giordano, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209615 · Cited by 1,216
Self-citationOn the road to cancer: aneuploidy and the mitotic checkpoint
Kops, G. J. P. L., Weaver, B. A. A., & Cleveland, D. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1714 · Cited by 1,185
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment
Shapiro, G. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.7689 · Cited by 1,036
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer
Lavin, M. F. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2514 · Cited by 901
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818
Chromosomal passengers: conducting cell division
Ruchaud, S., Carmena, M., & Earnshaw, W. C. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2257 · Cited by 811
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1
Vassilev, L. T., Tovar, C., Chen, S., Knezevic, D., Zhao, X., Sun, H., Heimbrook, D. C., & Chen, L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600447103 · Cited by 796
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
Ortega, S., Prieto, I., Odajima, J., Martín, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M., & Barbacid, M. (2003) · Nature Genetics · doi:10.1038/ng1232 · Cited by 796
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
Cyclin D-dependent kinases, INK4 inhibitors and cancer
Ortega, S., Malumbres, M., & Barbacid, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00037-9 · Cited by 778
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700
Berthet, C., Aleem, E., Coppola, V., Tessarollo, L., & Kaldis, P. (2003) · Current Biology · doi:10.1016/j.cub.2003.09.024 · Cited by 663
The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1
Lénárt, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J. J., Hoffmann, M., Rettig, W. J., Kraut, N., & Peters, J.-M. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.046 · Cited by 653
Polo-like kinases: conservation and divergence in their functions and regulation
Archambault, V., & Glover, D. M. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2653 · Cited by 604
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Whitehurst, A. W., Bodemann, B. O., Cardenas, J., Ferguson, D., Girard, L., Peyton, M., Minna, J. D., Michnoff, C., Hao, W., Roth, M. G., et al. (2007) · Nature · doi:10.1038/nature05697 · Cited by 474
Aurora-A: the maker and breaker of spindle poles
Barr, A. R., & Gergely, F. (2007) · Journal of Cell Science · doi:10.1242/jcs.013136 · Cited by 441
Kops, G. J. P. L., Foltz, D. R., & Cleveland, D. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401142101 · Cited by 437
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription
Takai, H., Naka, K., Okada, Y., Watanabe, M., Harada, N., Saito, S., Anderson, C. W., Appella, E., Nakanishi, M., Suzuki, H., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf506 · Cited by 436
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S., Haye, H. R., Horn, C. L., Janetka, J. W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0492 · Cited by 413
Targeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27 Kip1 Activity
Tsutsui, T., Hesabi, B., Moons, D. S., Pandolfi, P. P., Hansel, K. S., Koff, A., & Kiyokawa, H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7011 · Cited by 395
Byrd, J. C., Lin, T. S., Dalton, J. T., Wu, D., Phelps, M. A., Fischer, B., Moran, M., Blum, K. A., Rovin, B., Brooker-McEldowney, M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-020735 · Cited by 390
Polo-like kinases (Plks) and cancer
Takai, N., Hamanaka, R., Yoshimatsu, J., & Miyakawa, I. (2005) · Oncogene · doi:10.1038/sj.onc.1208272 · Cited by 386
Aurora Kinases as Anticancer Drug Targets
Gautschi, O., Heighway, J., Mack, P. C., Purnell, P. R., Lara, P. N., & Gandara, D. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2179 · Cited by 386
McClue, S. J., Blake, D., Clarke, R., Cowan, A., Cummings, L., Fischer, P. M., MacKenzie, M., Melville, J., Stewart, K., Wang, S., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10738 · Cited by 364
Wilkinson, R. W., Odedra, R., Heaton, S. P., Wedge, S. R., Keen, N. J., Crafter, C., Foster, J. R., Brady, M. C., Bigley, A., Brown, E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2979 · Cited by 356
Dimaras, H., Khetan, V., Halliday, W., Orlic, M., Prigoda, N. L., Piovesan, B., Marrano, P., Corson, T. W., Eagle, R. C., Squire, J. A., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn024 · Cited by 351
Jeyaprakash, A. A., Klein, U. R., Lindner, D., Ebert, J., Nigg, E. A., & Conti, E. (2007) · Cell · doi:10.1016/j.cell.2007.07.045 · Cited by 351
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Howard, S., Berdini, V., Boulstridge, J. A., Carr, M. G., Cross, D. M., Curry, J., Devine, L. A., Early, T. R., Fazal, L., Gill, A. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800984v · Cited by 333
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Goga, A., Yang, D., Tward, A. D., Morgan, D. O., & Bishop, J. M. (2007) · Nature Medicine · doi:10.1038/nm1606 · Cited by 326
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
Chen, Y.-N. P., Sharma, S. K., Ramsey, T. M., Jiang, L., Martin, M. S., Baker, K., Adams, P. D., Bair, K. W., & Kaelin, W. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4325 · Cited by 314
(2000) · PubMed · Cited by 314
Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion
Liu, X., Lei, M., & Erikson, R. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2093-2108.2006 · Cited by 303
Yang, J., Ikezoe, T., Nishioka, C., Tasaka, T., Taniguchi, A., Kuwayama, Y., Komatsu, N., Bandobashi, K., Togitani, K., Koeffler, H. P., et al. (2007) · Blood · doi:10.1182/blood-2007-02-073700 · Cited by 282
Mortlock, A. A., Foote, K. M., Heron, N. M., Jung, F. H., Pasquet, G., Lohmann, J.-J. M., Warin, N., Renaud, F., Savi, C. D., Roberts, N. J., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061335f · Cited by 270
Larochelle, S., Merrick, K. A., Terret, M.-E., Wohlbold, L., Barboza, N. M., Zhang, C., Shokat, K. M., Jallepalli, P. V., & Fisher, R. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.003 · Cited by 268
Rainey, M. D., Charlton, M. E., Stanton, R. V., & Kastan, M. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0763 · Cited by 266
Benson, C., White, J., Bono, J. D., O'Donnell, A., Raynaud, F., Cruickshank, C., McGrath, H., Walton, M., Workman, P., Kaye, S., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603509 · Cited by 261
p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.
Zhu, L., Harlow, E., & Dynlacht, B. D. (1995) · Genes & Development · doi:10.1101/gad.9.14.1740 · Cited by 252
Misra, R. N., Xiao, H.-Y., Kim, K. S., Lu, S., Han, W.-C., Barbosa, S. A., Hunt, J. T., Rawlins, D. B., Shan, W., Ahmed, S. Z., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0305568 · Cited by 252
Carpinelli, P., Ceruti, R., Giorgini, M. L., Cappella, P., Gianellini, L., Croci, V., Degrassi, A., Texido, G., Rocchetti, M., Vianello, P., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0444 · Cited by 245
Mechanisms of action of flavopiridol
Sedlacek, H. H. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00124-4 · Cited by 239
Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions
Reindl, W., Yuan, J., Krämer, A., Strebhardt, K., & Berg, T. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.03.013 · Cited by 232
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225
A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy
Perez de Castro, I., de Carcer, G., & Malumbres, M. (2006) · Carcinogenesis · doi:10.1093/carcin/bgm019 · Cited by 216
Claudio, P. P., Howard, C. M., Baldi, A., Luca, A. D., Fu, Y., Condorelli, G., Sun, Y., Colburn, N. H., Calabretta, B., & Giordano, A. (1994) · PubMed · Cited by 212
Self-citationSantamaria, A., Neef, R., Eberspächer, U., Eis, K., Husemann, M., Mumberg, D., Prechtl, S., Schulze, V., Siemeister, G., Wortmann, L., et al. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-05-0517 · Cited by 199
The crystal structure of cyclin A
Brown, N., Noble, M., Endicott, J., Garman, E., Wakatsuki, S., Mitchell, E., Rasmussen, B., Hunt, T., & Johnson, L. (1995) · Structure · doi:10.1016/s0969-2126(01)00259-3 · Cited by 191
Fancelli, D., Moll, J., Varasi, M., Bravo, R., Artico, R., Berta, D., Bindi, S., Cameron, A., Candiani, I., Cappella, P., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060897w · Cited by 188
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
Bettayeb, K., Oumata, N., Echalier, A., Ferandin, Y., Endicott, J. A., Galons, H., & Meijer, L. (2008) · Oncogene · doi:10.1038/onc.2008.191 · Cited by 184
Binné, U. K., Classon, M. K., Dick, F. A., Wei, W., Rape, M., Kaelin, W. G., Näär, A. M., & Dyson, N. J. (2007) · Nature Cell Biology · doi:10.1038/ncb1532 · Cited by 175
Matsuura, S., Matsumoto, Y., Morishima, K., Izumi, H., Matsumoto, H., Ito, E., Tsutsui, K., Kobayashi, J., Tauchi, H., Kajiwara, Y., et al. (2006) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31069 · Cited by 173
Squires, M. S., Feltell, R. E., Wallis, N. G., Lewis, E. J., Smith, D.-M., Cross, D. M., Lyons, J. F., & Thompson, N. T. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0890 · Cited by 171
Strock, C. J., Park, J.-I., Nakakura, E. K., Bova, G. S., Isaacs, J. T., Ball, D. W., & Nelkin, B. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3048 · Cited by 163
Shaheen, R. M., Tseng, W. W., Davis, D. W., Liu, W., Reinmuth, N., Vellagas, R., Wieczorek, A. A., Ogura, Y., McConkey, D. J., Drazan, K. E., et al. (2001) · PubMed · Cited by 162
Mross, K., Frost, A., Steinbild, S., Hedbom, S., Rentschler, J., Kaiser, R., Rouyrre, N., Trommeshauser, D., Hoesl, C. E., & Munzert, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1547 · Cited by 158
Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue.
Seynaeve, C., Kazanietz, M. G., Blumberg, P. M., Sausville, E. A., & Worland, P. J. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10590-7 · Cited by 158
Menoyo, A., Alazzouzi, H., Espín, E., Armengol, M., Yamamoto, H., & Schwartz, S. (2001) · PubMed · Cited by 151
Guan, R., Tapang, P., Leverson, J. D., Albert, D., Giranda, V. L., & Luo, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2131 · Cited by 148
Matthews, D. J., Yakes, M., Chen, J., Tadano, M., Bornheim, L. M., Clary, D. O., Tai, A., Wagner, J. M., Miller, N., Kim, Y. D., et al. (2007) · Cell Cycle · doi:10.4161/cc.6.1.3699 · Cited by 141
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
Lansing, T. J., McConnell, R. T., Duckett, D. R., Spehar, G. M., Knick, V. B., Hassler, D. F., Noro, N., Furuta, M., Emmitte, K. A., Gilmer, T. M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0543 · Cited by 140
Polo and Aurora kinases — lessons derived from chemical biology
Taylor, S. S., & Peters, J. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.11.008 · Cited by 131
Mice thrive without Cdk4 and Cdk2
Barrière, C., Santamaría, D., Cerqueira, A., Galán, J., Martín, A., Ortega, S., Malumbres, M., Dubus, P. R., & Barbacid, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.03.001 · Cited by 130
Molecular Basis of Drug Resistance in Aurora Kinases
Girdler, F., Sessa, F., Patercoli, S., Villa, F., Musacchio, A., & Taylor, S. S. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.04.013 · Cited by 128
Lin, R., Connolly, P. J., Huang, S., Wetter, S. K., Lü, Y., Murray, W. V., Emanuel, S. L., Gruninger, R. H., Fuentes‐Pesquera, A. R., Rugg, C. A., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050267e · Cited by 127
Emanuel, S. L., Rugg, C. A., Gruninger, R. H., Lin, R., Fuentes‐Pesquera, A. R., Connolly, P. J., Wetter, S. K., Hollister, B. A., Kruger, W. W., Napier, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0882 · Cited by 127
Mutations in the Plk gene lead to instability of Plk protein in human tumour cell lines
Simizu, S., & Osada, H. (2000) · Nature Cell Biology · doi:10.1038/35041102 · Cited by 124
Martín, J., Hunt, S. L., Dubus, P., Sotillo, R., Néhmé-Pélluard, F., Magnuson, M. A., Parlow, A. F., Malumbres, M., Ortega, S., & Barbacid, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206506 · Cited by 122
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
Joshi, K., Rathos, M. J., Joshi, R., Sivakumar, M., Mascarenhas, M., Kamble, S., Lal, B., & Sharma, S. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0613 · Cited by 121
Ablation of the spindle assembly checkpoint by a compound targeting Mps1
Schmidt, M., Budirahardja, Y., Klompmaker, R., & Medema, R. H. (2005) · EMBO Reports · doi:10.1038/sj.embor.7400483 · Cited by 120
A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis
Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G., Chang, R., Guo, Z., Dose, M., Mao, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2473 · Cited by 119
García‐Álvarez, B., de Cárcer, G., Ibañez, S., Bragado‐Nilsson, E., & Montoya, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609131104 · Cited by 117
Mechanisms of Mitotic Cell Death Induced by Chemotherapy-Mediated G2 Checkpoint Abrogation
Vogel, C., Hager, C., & Bastians, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2548 · Cited by 115
p130 and p107 Use a Conserved Domain To Inhibit Cellular Cyclin-Dependent Kinase Activity†
Woo, M. S., Sánchez, I., & Dynlacht, B. D. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.3566 · Cited by 114
Romano, G., & Giordano, A. (2008) · Cell Cycle · doi:10.4161/cc.7.23.7122 · Cited by 113
Self-citationRole of Checkpoint Kinase 1 in Preventing Premature Mitosis in Response to Gemcitabine
Morgan, M. A., Parsels, L. A., Parsels, J. D., Mesiwala, A. K., Maybaum, J., & Lawrence, T. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2246 · Cited by 109
A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
Menu, E., García, J., Huang, X., Liberto, M. D., Toogood, P. L., Chen, I., Vanderkerken, K., & Chen‐Kiang, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6404 · Cited by 108
Cyclin-Dependent Kinase 4 Expression Is Essential for Neu-Induced Breast Tumorigenesis
Reddy, H. K. D. L., Mettus, R. V., Rane, S. G., Graña, X., Litvin, J., & Reddy, E. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2639 · Cited by 108
Vassileva, V., Millar, A., Briollais, L., Chapman, W. B., & Bapat, B. V. (2002) · PubMed · Cited by 107
Functional analysis of pRb2/p130 interaction with cyclins.
Claudio, P. P., Luca, A. D., Howard, C. M., Baldi, A., Firpo, E. J., Koff, A., Paggi, M. G., & Giordano, A. (1996) · PubMed · Cited by 107
Self-citationDePinto, W., Chu, X., Yin, X., Smith, M., Packman, K. E., Goelzer, P., Lovey, A. J., Chen, Y., Qian, H., Hamid, R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0355 · Cited by 106
Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
Smalley, K. S. M., Contractor, R., Nguyen, T. K., Xiao, M., Edwards, R. H., Muthusamy, V., King, A. J., Flaherty, K. T., Bosenberg, M., Herlyn, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0235 · Cited by 106
Claudio, P. P., Howard, C. M., Pacilio, C., Cinti, C., Romano, G., Minimo, C., Maraldi, N. M., Minna, J. D., Gelbert, L. M., Leoncini, L., et al. (2000) · PubMed · Cited by 105
Self-citationGodl, K., Gruß, O. J., Eickhoff, J., Wissing, J. B., Blencke, S., Weber, M., Degen, H., Brehmer, D., Őrfi, L., Horváth, Z., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0574 · Cited by 105
Lack of Cyclin-Dependent Kinase 4 Inhibits c- myc Tumorigenic Activities in Epithelial Tissues
de Marval, P. L. M., Macias, E., Rounbehler, R. J., Siciński, P., Kiyokawa, H., Johnson, D. G., Conti, C. J., & Rodríguez‐Puebla, M. L. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7538-7547.2004 · Cited by 101
CDK11p58 is required for the maintenance of sister chromatid cohesion
Hu, D., Valentine, M. B., Kidd, V. J., & Lahti, J. M. (2007) · Journal of Cell Science · doi:10.1242/jcs.007963 · Cited by 98
Xiao, Z., Xue, J., Sowin, T. J., & Zhang, H. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0077 · Cited by 98
Cdk11 is a RanGTP-dependent microtubule stabilization factor that regulates spindle assembly rate
Yokoyama, H., Gruß, O. J., Rybina, S., Caudron‐Herger, M., Schelder, M., Wilm, M. S., Mattaj, I. W., & Karsenti, E. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200706189 · Cited by 89
Carlessi, L., Buscemi, G., Larson, G., Hong, Z., Wu, J. Z., & Delia, D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0567 · Cited by 89
Walsby, E. J., Walsh, V., Pepper, C. J., Burnett, A. K., & Mills, K. (2008) · Haematologica · doi:10.3324/haematol.12148 · Cited by 88
The retinoblastoma family: twins or distant cousins?
Claudio, P. P., Tonini, T., & Giordano, A. (2002) · Genome biology · doi:10.1186/gb-2002-3-9-reviews3012 · Cited by 87
Self-citationTao, Y., Zhang, P., Girdler, F., Frascogna, V., Castedo, M., Bourhis, J., Kroemer, G., & Deutsch, É. (2007) · Oncogene · doi:10.1038/sj.onc.1210990 · Cited by 86
Dorer, R. K., Zhong, S., Tallarico, J. A., Wong, W. H., Mitchison, T. J., & Murray, A. W. (2005) · Current Biology · doi:10.1016/j.cub.2005.05.020 · Cited by 86
Li, T., Inoue, A., Lahti, J. M., & Kidd, V. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3188-3197.2004 · Cited by 86
Retinoblastoma family proteins: insights gained through genetic manipulation of mice
Wikenheiser-Brokamp, K. A. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5487-3 · Cited by 85
Lining the pockets of kinases and phosphatases
Gold, M. G., Barford, D., & Komander, D. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.10.006 · Cited by 85
Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors
Payton, M. N., Chung, G., Yakowec, P. S., Wong, A., Powers, D., Xiong, L., Zhang, N., Martínez-Leal, J. F., Bush, T. L., Santora, V. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2507 · Cited by 83
Talbot, D. C., von Pawel, J., Cattell, E., Yule, S. M., Johnston, C., Zandvliet, A. S., Huitema, A. D. R., Norbury, C. J., Ellis, P., Bosquée, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0249 · Cited by 83
The RB family of cell cycle regulatory factors
Stiegler, P., Kasten, M. M., & Giordano, A. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1998)72:30/31+<30::aid-jcb5>3.0.co;2-j · Cited by 82
Self-citationA Unique Domain of pRb2/p130 Acts as an Inhibitor of Cdk2 Kinase Activity
Luca, A. D., MacLachlan, T. K., Bagella, L., Dean, C., Howard, C. M., Claudio, P. P., Baldi, A., Khalili, K., & Giordano, A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.20971 · Cited by 82
Self-citationCritical requirement for cell cycle inhibitors in sustaining nonproliferative states
Pajalunga, D., Mazzola, A., Salzano, A. M., Biferi, M. G., Luca, G. D., & Crescenzi, M. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200608109 · Cited by 81
Garland, L. L., Taylor, C., Pilkington, D., Cohen, J. L., & Hoff, D. D. V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0214 · Cited by 80
Rodríguez‐Puebla, M. L., de Marval, P. L. M., LaCava, M., Moons, D. S., Kiyokawa, H., & Conti, C. J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64196-x · Cited by 76
Popowycz, F., Fournet, G., Schneider, C., Bettayeb, K., Ferandin, Y., Lamigeon, C., Tirado, Ò. M., Mateo‐Lozano, S., Notario, V., Colas, P., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801340z · Cited by 76
Cdk4 Is Indispensable for Postnatal Proliferation of the Anterior Pituitary
Jirawatnotai, S., Aziyu, A., Osmundson, E. C., Moons, D. S., Zou, X., Kineman, R. D., & Kiyokawa, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409080200 · Cited by 76
Aurora A and B kinases as targets for cancer: will they be selective for tumors?
Matthews, N., Visintin, C., Hartzoulakis, B., Jarvis, A., & Selwood, D. L. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.1.109 · Cited by 76
Cai, D. D., Byth, K. F., & Shapiro, G. I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1769 · Cited by 74
Joshi, K., Rathos, M. J., Mahajan, P., Wagh, V., Shenoy, S. S., Bhatia, D. R., Chile, S., Sivakumar, M., Maier, A., Fiebig, H., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0614 · Cited by 74
Pennati, M., Campbell, A. J., Curto, M., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0022 · Cited by 72
Cellular effects of purvalanol A: A specific inhibitor of cyclin‐dependent kinase activities
Villerbu, N., Gaben, A., Redeuilh, G., & Mešter, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.10125 · Cited by 71
Mendoza, N., Fong, S., Marsters, J., Koeppen, H., SCHWALL, R. H., & Wickramasinghe, D. (2003) · PubMed · Cited by 71
Keeping checkpoint kinases in line: new selective inhibitors in clinical trials
Ashwell, S., Janetka, J. W., & abludoff, S. Z. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.9.1331 · Cited by 70
Ivanov, V. N., Zhou, H., Partridge, M. A., & Hei, T. K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3883 · Cited by 69
Raje, N. S., Hideshima, T., Mukherjee, S., Raab, M. S., Vallet, S., Chhetri, S., Cirstea, D. D., Pozzi, S., Mitsiades, C. S., Rooney, M., et al. (2009) · Leukemia · doi:10.1038/leu.2008.378 · Cited by 68
Who is the boss in the retinoblastoma family? The point of view of Rb2/p130, the little brother.
Paggi, M. G., & Giordano, A. (2001) · PubMed · Cited by 65
Self-citationScutt, P. J., Chu, M. L.-H., Sloane, D. A., Cherry, M., Bignell, C. R., Williams, D. H., & Eyers, P. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.005694 · Cited by 64
Seamon, J. A., Rugg, C. A., Emanuel, S. L., Calcagno, A. M., Ambudkar, S. V., Middleton, S. A., Butler, J., Borowski, V., & Greenberger, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0339 · Cited by 63
Jobson, A. G., Cardellina, J. H., Scudiero, D. A., Kondapaka, S. B., Zhang, H., Kim, H., Shoemaker, R. H., & Pommier, Y. G. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035832 · Cited by 62
Siemeister, G., Luecking, U., Wagner, C., Detjen, K. M., Coy, C. M., & Bosslet, K. (2006) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2006.06.003 · Cited by 62
Flavopiridol in the treatment of chronic lymphocytic leukemia
Christian, B. A., Grever, M. R., Byrd, J. C., & Lin, T. S. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282efb9da · Cited by 58
A nonsense mutation (E1978X) in the ATM gene is associated with breast cancer
Bogdanova, N. V., Cybulski, C., Bermisheva, M., Datsyuk, I., Yamini, P., Hillemanns, P., Antonenkova, N. N., Хуснутдинова, Э. К., Lubiński, J., & Dörk, T. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0189-9 · Cited by 56
N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine
Bettayeb, K., Sallam, H., Ferandin, Y., Popowycz, F., Fournet, G., Hassan, M., Echalier, A., Bernard, P., Endicott, J., Joseph, B., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0080 · Cited by 56
Canela-Canela, N., Orzáez, M., Fucho, R., Mateo, F., Gallego, R. G., Pineda‐Lucena, A., Bachs, O., & Pérez‐Payá, E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603511200 · Cited by 55
Anderson, K., Lai, Z., McDonald, O. B., Stuart, J. D., Nartey, E. N., Hardwicke, M. A., Newlander, K. A., Dhanak, D., Adams, J. L., Patrick, D. R., et al. (2009) · Biochemical Journal · doi:10.1042/bj20090121 · Cited by 55
Howard, C. M., Claudio, P. P., Luca, A. D., Stiegler, P., Jori, F. P., Safdar, N. M., Caputi, M., Khalili, K., & Giordano, A. (2000) · PubMed · Cited by 51
Self-citationSha, S.-K., Sato, T., Kobayashi, H., Ishigaki, M., Yamamoto, S., Sato, H., Takada, A., Nakajyo, S., Mochizuki, Y., Friedman, J. M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0371 · Cited by 51
Byth, K. F., Geh, C., Forder, C. L., Oakes, S. E., & Thomas, A. P. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0205 · Cited by 48
Takagi, M., Honmura, T., Watanabe, S., Yamaguchi, R., Nogawa, M., Nishimura, I., Katoh, F., Matsuda, M., & Hidaka, H. (2003) · Investigational New Drugs · doi:10.1023/a:1026282716250 · Cited by 45
Bagella, L., Sun, A., Tonini, T., Abbadessa, G., Cottone, G., Paggi, M. G., Luca, A. D., Claudio, P. P., & Giordano, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209987 · Cited by 45
Self-citationCharacterization ofCHEK2 mutations in prostate cancer
Wu, X., Dong, X., Liu, W., & Chen, J. (2006) · Human Mutation · doi:10.1002/humu.20321 · Cited by 41
Kodym, E., Kodym, R., Reis, A. E., Habib, A. A., Story, M. D., & Saha, D. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.12.026 · Cited by 40
Scholz, A., Wagner, K. G., Welzel, M., Remlinger, F., Wiedenmann, B., Siemeister, G., Rosewicz, S., & Detjen, K. M. (2008) · Gut · doi:10.1136/gut.2007.146415 · Cited by 38
Development and Biological Evaluation of a Novel Aurora A Kinase Inhibitor
Sardón, T., Cottin, T., Xu, J., Giannis, A., & Vernos, I. (2009) · ChemBioChem · doi:10.1002/cbic.200800600 · Cited by 35
Scott, E. N., Thomas, A., Molife, L. R., Ahmed, S. I., Blagden, S. P., Fong, P. C. C., Kowal, K., McCoy, C., Wiesinger, H., Steward, W. P., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0968-y · Cited by 34
Diab, S., Eckhardt, S. G., Tan, A. R., Frenette, G., Gore, L., DePinto, W., Grippo, J. F., DeMario, M., Mikulski, S. M., & Papadimitrakopoulou, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3528 · Cited by 29
Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors
Xiao, Z., Xue, J., Gu, W., Bui, M. H., Li, G., Tao, Z., Lin, N., Sowin, T. J., & Zhang, H. (2008) · Biomarkers · doi:10.1080/13547500802063240 · Cited by 27
Renshaw, J., Patnaik, A., Gordon, M. S., Beeram, M., Fischer, D., Gianella-Borradori, A., Lin, C., & Mendelson, D. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.14130 · Cited by 26
Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice
Chandramouli, A., Shi, J., Feng, Y., Holubec, H., Shañas, R., Bhattacharyya, A. K., Zheng, W., & Nelson, M. A. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm066 · Cited by 25
Shapiro, G. I., Bannerji, R., Small, K. A., Black, S., Statkevich, P., Abutarif, M. A., Moseley, J. L., Yao, S., Takimoto, C. H. M., & Mita, M. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3532 · Cited by 23
Brown, A. P., Courtney, C. L., Criswell, K. A., Holliman, C. L., Evering, W., & Jessen, B. A. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0771-1 · Cited by 19
Yuen, K. W. Y., & Desai, A. B. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200801030 · Cited by 15
A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties
Choong, I., Serafimova, I. M., Fan, J., Stockett, D. E., Chan, E., Cheeti, S., Lu, Y., Fahr, B. J., Pham, P., Arkin, M. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.09.073 · Cited by 11
Owa, T., Yoshino, H., Okauchi, T., Okabe, T., Ozawa, Y., Sugi, N. H., Yoshimatsu, K., Nagasu, T., Koyanagi, N., & Kitoh, K. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00376-1 · Cited by 10
AG-024322 is a multi-targeted CDK inhibitor with potent antitumor activity in vivo
Zhang, C. C., Troche, G. E., Yan, Z., et al. (2005) · Cancer Research · Cited by 9
Zhang, C. C., Kephart, S. E., McAlpine, I., et al. (2005) · Cancer Research · Cited by 8
Fan, J., Fahr, B. J., Stockett, D. E., Chan, E., Cheeti, S., Serafimova, I. M., Lu, Y., Pham, P., Walker, D. H., Hoch, U., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.09.099 · Cited by 6
Cited by
Chemistry and Biology Of Multicomponent Reactions
Dömling, A., Wang, W., & Wang, K. (2012) · Chemical Reviews · doi:10.1021/cr100233r · Cited by 2,547
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Cyclin D as a therapeutic target in cancer
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3090 · Cited by 1,370
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Metadata
- Authors
- Lapenna, S., & Giordano, A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2009-07
- Volume
- 8
- Issue
- 7
- Pages
- 547-566
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074918415
- Cited by
- 905
- References
- 166
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.